NRX Pharmaceuticals (NRXP) Total Non-Current Liabilities (2021 - 2026)

NRX Pharmaceuticals (NRXP) has 5 years of Total Non-Current Liabilities data on file, last reported at $17.0 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 25.97% year-over-year to $17.0 million in Q1 2026; TTM through Mar 2026 was $17.0 million, a 25.97% decrease from a year earlier, with the FY2025 full-year figure at $16.6 million, down 21.88% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $17.0 million, up from $16.6 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for NRXP reached as high as $24.9 million in Q3 2025 and fell as low as $16.6 million in Q4 2025.
• Historically, Total Non-Current Liabilities has averaged $21.2 million across 4 years, with a median of $21.4 million in 2024.
• Across the five-year window, Total Non-Current Liabilities advanced 16.41% in 2025 and slipped 25.97% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $19.0 million in 2023, then increased by 11.58% to $21.2 million in 2024, then decreased by 21.88% to $16.6 million in 2025, then gained by 2.19% to $17.0 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $17.0 million in Q1 2026, $16.6 million in Q4 2025, and $24.9 million in Q3 2025.